Pediatric acute kidney injury induced by concomitant vancomycin and piperacillin–tazobactam

Pediatric acute kidney injury induced by concomitant vancomycin and piperacillin–tazobactam Vancomycin is a glycopeptide antibiotic commonly used in combination with other β‐lactam antibiotics, such as piperacillin–tazobactam (PTZ), as the initial empiric treatment for moderate–severe infections whenever coverage for both methicillin‐resistant Staphylococcus aureus and Pseudomonas aeruginosa is required.Vancomycin use has long been reported to be associated with nephrotoxicity. The development of acute kidney injury (AKI) in hospitalized patients can increase both morbidity and mortality. The published incidence of vancomycin‐induced AKI ranges from 5% to 43%, depending largely on the population studied, the presence or absence of confounding risk factors, and definitions of nephrotoxicity. In contrast, the reported incidence of AKI in patients receiving PTZ monotherapy is <1%.Several risk factors that increase the risk of vancomycin nephrotoxicity have been identified, including concomitant nephrotoxic agents, pre‐existing renal dysfunction, concomitant critical illness, increasing treatment duration, higher vancomycin serum trough concentration (>15 μg/mL), and total vancomycin dosage >4 g/day in adults.The exact mechanism of vancomycin nephrotoxicity is still uncertain. Vancomycin is primarily eliminated by glomerular filtration and some active tubular secretion. Postulated mechanisms include oxidative stress, complement‐mediated inflammation, and necrosis of the renal tubule with vancomycin accumulation. Published reports evaluating PTZ nephrotoxic potential are sparse. PTZ has been implicated in AKI through acute interstitial nephritis (AIN) http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Pediatrics International Wiley

Pediatric acute kidney injury induced by concomitant vancomycin and piperacillin–tazobactam

Loading next page...
 
/lp/wiley/pediatric-acute-kidney-injury-induced-by-concomitant-vancomycin-and-JebKWalbl1
Publisher
Wiley
Copyright
Copyright © 2018 Japan Pediatric Society
ISSN
1328-8067
eISSN
1442-200X
D.O.I.
10.1111/ped.13463
Publisher site
See Article on Publisher Site

Abstract

Vancomycin is a glycopeptide antibiotic commonly used in combination with other β‐lactam antibiotics, such as piperacillin–tazobactam (PTZ), as the initial empiric treatment for moderate–severe infections whenever coverage for both methicillin‐resistant Staphylococcus aureus and Pseudomonas aeruginosa is required.Vancomycin use has long been reported to be associated with nephrotoxicity. The development of acute kidney injury (AKI) in hospitalized patients can increase both morbidity and mortality. The published incidence of vancomycin‐induced AKI ranges from 5% to 43%, depending largely on the population studied, the presence or absence of confounding risk factors, and definitions of nephrotoxicity. In contrast, the reported incidence of AKI in patients receiving PTZ monotherapy is <1%.Several risk factors that increase the risk of vancomycin nephrotoxicity have been identified, including concomitant nephrotoxic agents, pre‐existing renal dysfunction, concomitant critical illness, increasing treatment duration, higher vancomycin serum trough concentration (>15 μg/mL), and total vancomycin dosage >4 g/day in adults.The exact mechanism of vancomycin nephrotoxicity is still uncertain. Vancomycin is primarily eliminated by glomerular filtration and some active tubular secretion. Postulated mechanisms include oxidative stress, complement‐mediated inflammation, and necrosis of the renal tubule with vancomycin accumulation. Published reports evaluating PTZ nephrotoxic potential are sparse. PTZ has been implicated in AKI through acute interstitial nephritis (AIN)

Journal

Pediatrics InternationalWiley

Published: Jan 1, 2018

Keywords: ; ; ; ;

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off